Sipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer

Figures & data

Figure 1. GM-CSF/PAP fusion protein is incubated with patients' WBC for APC activation and loading with PAP peptide. Cultured APC are infused to patient which then mobilize anti-PAP T cells. When these cells recognize a prostate tumor with PAP peptide, they deliver a lethal hit. MDSC can block this activity and render an immune response ineffective. Perhaps conditions favorable for eosinophil accumulation prevent MDSC generation or function.

Figure 2. . The developmental timeline for Sipuleucel-T (Provenge)

Table 1. Comparison of Treatments for Castrate Resistant Metastatic Prostate Cancer

Agent (Trial Name)	Patients	Median OS	Main Toxicities
Sipuleucel-T (IMPACT) Sip-T Control	512 341 171	4.1 25.8 21.7	Infusions related fever, chills, myalgia,
Abiraterone (Cou-301) Abiraterone and Prednisone Prednisone alone	1195 797 398	3.9 14.8 10.9	Hypokalemia, Hypertension, Fluid Retention, Fatigue
Cabaxitaxel (TROPIC) Cabaxitaxel Mitoxantrone	755 378 377	15.1 12.7	Febrile Neutropenia, Diarrhea
MDV3100 (AFFIRM) MDV3100 Placebo	1199 800 399	4.8 18.4 13.6	Fatigue